Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic tumor resulting from the malignant transformation of immature T-cell progenitor cells and constitutes 15% of pediatric and 25% of adult ALL cases. 1, 2 Initially associated with very poor prognosis, T-ALL can now be cured in about 80% of children and 50% of adults; thanks to the use of highly intensive chemotherapy protocols. [3] [4] [5] [6] [7] [8] [9] Despite this progress, leukemia relapse, generally associated with acquired chemotherapy resistance, still constitutes a significant clinical problem. [9] [10] [11] In this context, the development of new drugs and drug combinations effective against relapsed T-ALL has become a priority in the field.
Activating mutations in the NOTCH1 gene are present in over 50% of human T-ALL cases making NOTCH1 the most prominent oncogene specifically involved in the pathogenesis of this disease. [12] [13] [14] [15] [16] It is important to note that the activation of NOTCH1 signaling requires its proteolytic processing by the presenilin-g secretase complex. 17, 18 Consequently, small molecule g-secretase inhibitors (GSIs) effectively block NOTCH1 activity in T-ALL cells and have been proposed as a molecularly targeted therapy for the treatment of this disease. 12 However, animal studies have shown that systemic inhibition of NOTCH signaling results in gastrointestinal toxicity because of the accumulation of secretory goblet cells in the intestine. [19] [20] [21] [22] In agreement with these results, a phase-I clinical trial analyzing the effects of a GSI in relapsed and refractory T-ALL showed significant gastrointestinal toxicity. 23 Moreover, none of the patients enrolled in this study showed any significant clinical response, which correlates with the weak antileukemic effects of GSIs against human T-ALL cells in vitro. 23 Despite these unsatisfactory results in the clinic, inhibition of NOTCH1 signaling has a profound effect on the homeostasis of T-ALL lymphoblasts, [24] [25] [26] suggesting that GSIs may sensitize T-ALL cells to chemotherapy. In this feature, we summarize our results showing that GSIs may reverse glucocorticoid resistance in T-ALL and that glucocorticoid therapy may antagonize the effects of NOTCH inhibition in the intestinal epithelium and protect from GSI-induced gut toxicity. 27 Inhibition of NOTCH1 signaling with GSIs reverses glucocorticoid resistance in T-ALL Glucocorticoids play a fundamental role in the treatment of all lymphoid tumors because of their capacity to induce apoptosis in lymphoid progenitor cells. 2, 28, 29 The importance of glucocorticoid therapy in leukemias and lymphomas is underscored by the strong association of glucocorticoid response with prognosis in childhood ALL. Thus, the initial response to 7 days of glucocorticoid therapy is a strong independent prognostic factor in this disease. 6, 30, 31 Resistance to glucocorticoids in vitro is associated with an unfavorable prognosis. 32, 33 Moreover, the majority of patients with ALL in relapse show increased resistance to glucocorticoid therapy, identifying glucocorticoid resistance as a major contributor to treatment failure. 32, 34 NOTCH1 signaling plays a critical role in promoting cell growth, proliferation and survival in immature T-cells, which is in a way opposed to glucocorticoid-induced cell death. 35 Indeed, constitutive activation of NOTCH1 signaling may protect developing thymocytes against glucocorticoid-induced apoptosis. 36 To address the relevance of this interaction in the context of oncogenic NOTCH1 signaling, we tested the effects of GSIs and dexamethasone in T-ALL cells. 27 These studies showed that inhibition of NOTCH1 with GSIs sensitized glucocorticoid-resistant T-ALL cell lines and primary samples to glucocorticoid-induced apoptosis. This synergistic interaction was mediated by inhibition of NOTCH1 signaling and required activation of the glucocorticoid receptor. 27 Interestingly, we did not observe a synergistic effect of GSIs and glucocorticoids in glucocorticoid-sensitive cells, suggesting that the increased antileukemic effects of GSIs plus glucocorticoids are specifically mediated by reversal of glucocorticoid resistance. 27 Finally, these results did not extend to other chemotherapy drugs such as etoposide, methotrexate, vincristine and L-asparaginase. 27 Gene expression profiling analysis of the effects of GSI plus dexamethasone treatment in the CUTLL1 cell line showed increased expression of the glucocorticoid receptor (NR3C1) and glucocorticoid-regulated genes. 27 It is noted that the amplification of glucocorticoid receptor signaling through glucocorticoid receptor auto-upregulation is essential for glucocorticoid-induced apoptosis, and loss of glucocorticoid receptor auto-upregulation has been proposed as a prevalent mechanism of glucocorticoid resistance in ALL. [37] [38] [39] [40] [41] [42] In addition, retroviral expression of the glucocorticoid receptor was sufficient to restore glucocorticoid sensitivity in these cells. 27 A mechanistic link between NOTCH1 signaling and glucocorticoid receptor autoupregulation was established by showing that HES1, a transcriptional repressor controlled by NOTCH1, binds to each of the three glucocorticoid receptor promoters involved in glucocorticoid receptor auto-upregulation in T-ALL. 27 Moreover, HES1 inactivation via shRNA knockdown resulted in glucocorticoid receptor upregulation and restored glucocorticoid sensitivity. 27 Consistent with this model, Bim, a critical apoptotic factor in glucocorticoid-induced cell death, was shown to be synergistically upregulated in cells treated with dexamethasone plus a GSI. 27 In vivo validation of these results showed the efficiency of combined treatment of GSI and glucocorticoids in a xenograft model of glucocorticoid-resistant T-ALL.
Glucocorticoid treatment protects from GSI-induced gut toxicity
An unexpected finding in these experiments was that glucocorticoid treatment seemed to have a protective effect against GSI-induced intestinal toxicity in mice. 27 These surprising results were confirmed using an inducible model of Notch inactivation using CSL/Rbpj conditional knockout mice. 27 Moreover, dexamethasone treatment did not result in increased GSI metabolism, ruling out that the decrease in GSI-induced gut toxicity by dexamethasone was mediated by a pharmacokinetic interaction. 27 The function of Klf4, a transcription factor inhibitor of cell cycle progression and a critical factor required for the generation of intestinal goblet cells, 43, 44 is related to the two main histological features associated with GSI-induced gut toxicity, namely, the accumulation of secretory goblet cells and a prominent block in cell proliferation. We observed that Klf4 is markedly upregulated in the intestine of mice treated with a GSI and showed that NOTCH1 negatively regulates Klf4 through HES1-mediated control of the Klf4 promoter. 27 Overall, these findings identify Klf4 as an indirect target downregulated by NOTCH1 signaling and by a critical mediator of GSI-induced gut toxicity. Now the open question is: how does dexamethasone abrogate Klf4 upregulation? To address this question, we first analyzed the effects of glucocorticoid treatment in the intestine. Detailed histological and gene expression profiling have shown that dexamethasone treatment leads to the accumulation of lysozyme-positive Paneth cells at the bottom of the crypt and increased cell proliferation associated with increased expression of Ccnd2. 27 Analysis of Ccnd2 deficient animals showed that dexamethasone treatment failed to protect Ccnd2 knock out mice from developing GSI-induced goblet cell metaplasia. 27 Overall these results show a role of glucocorticoids in the control of cell homeostasis in the intestinal epithelium and identify Ccnd2 as a critical mediator of the enteroprotective effects of glucocorticoids against GSI-induced gut toxicity.
Concluding remarks and future directions
Despite the central role of glucocorticoids in the treatment of lymphoid malignancies and the importance of glucocorticoid resistance in the clinic, the molecular mechanisms that mediate glucocorticoid resistance in ALL have not been resolved. Among other mechanisms, several groups have proposed alterations in the upregulation of glucocorticoid receptor expression in response to glucocorticoids as a possible mechanism mediating glucocorticoid resistance in ALL. [37] [38] [39] [40] [41] [42] The results of our studies show that oncogenic transcriptional networks and signaling pathways can modulate the activity of the glucocorticoid receptor and hence the therapeutic response to glucocorticoids in lymphoid tumors. Moreover the identification of a NOTCH1-HES1-glucocorticoid receptor regulatory axis highlights a critical role for glucocorticoid receptor auto-upregulation in glucocorticoid-induced apoptosis and glucocorticoid response. However, this is in contrast with recent studies showing effective glucocorticoid receptor upregulation in glucocorticoid resistant ALL cells. 45 In addition, even though activating mutations in NOTCH1 are highly prevalent, most T-ALLs show adequate responses to glucocorticoid therapy and NOTCH1 mutations do not seem to confer poor prognosis in T-ALL. 16, 46 An important factor that may account for these discrepant results is the difference between primary glucocorticoid resistance at diagnosis, in which the glucocorticoid receptor autoregulatory loop seems to be competent; and secondary glucocorticoid resistance at relapse, in which a fraction of ALL samples seem to have attenuated glucocorticoid receptor auto-upregulation. Given that most NOTCH1 mutated cases are sensitive to glucocorticoids, attenuation of glucocorticoid receptor autoupregulation by NOTCH1-HES1 is most probably not sufficient to effectively block glucocorticoid-induced apoptosis. However, release of this inhibitory effect by GSIs seems to be sufficient to trigger a more robust glucocorticoid response and glucocorticoid-induced apoptosis in otherwise glucocorticoid-resistant T-ALL cells.
The interaction of glucocorticoids and GSIs in the intestine, which results in abrogation of GSI-induced gut toxicity, has uncovered an earlier unrecognized effect of glucocorticoid therapy in the intestinal epithelium. Our results show that glucocorticoids promote Paneth cell differentiation and promote cell proliferation in part through upregulation of Ccnd2 expression. Notably, downregulation of Klf4, a critical factor involved in GSI-induced gut toxicity by Ccnd2 seems to play a critical role in preventing GSI-induced goblet cell differentiation. However, several important questions regarding the mechanistic interaction between GSIs and glucocorticoids in the gut remain to be elucidated. How does dexamethasone affect Paneth cell differentiation? Is Ccnd2 a direct transcriptional target of glucocorticoids in the gut? What is the specific mechanism that mediates Klf4 downregulation by Ccnd2?
Overall, our data on the interaction between glucocorticoids and GSIs supports the development of clinical trials aiming to test the safety and efficacy of GSIs and glucocorticoids in T-ALL. 27 In addition, numerous recent reports have described a role for aberrant NOTCH signaling in the pathogenesis of solid tumors [47] [48] [49] [50] [51] [52] and tumor angiogenesis, [53] [54] [55] [56] [57] [58] suggesting a broader role for anti-NOTCH therapies and glucocorticoids in the treatment of human cancer. Moreover, the enteroprotective effects of glucocorticoids against GSI-induced gut toxicity may open new opportunities for the use of GSIs in the treatment of Alzheimer's disease. However, chronic glucocorticoid treatment is associated with significant toxicities and the combination of GSIs and glucocorticoids has a deleterious effect in the immune system. Scaling down the dose of glucocorticoids may reduce these undesired toxic effects while still protecting from the development of GSI-induced gut toxicity. In addition, improved understanding of the mechanisms mediating the enteroprotective NOTCH1 inhibitors and glucocorticoid therapy PJ Real and AA Ferrando effect of glucocorticoids should facilitate the identification of additional genes and pathways that can be targeted to prevent GSI-induced gut toxicity.
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